

Data Item Numerical	NAACCR Item Number
NAACCR Record Version	50
Tumor Record Number	60
Address at Dx City	70
Address at Dx State	80
FIPS County Code at Dx	90
Address at Dx Zip Code	100
Address at Dx Country	102
Marital Status at Dx	150
Race 1	160
Race 2	161
Race 3	162
Race 4	163
Race 5	164
Spanish/Hispanic Origin	190
Sex	220
Age at Diagnosis	230
Date of Birth	240
Birthplace - State	252
Birthplace - Country	254
Text Usual Occupation	310
Text Usual Industry	320
Tobacco Use Smoking Status	344
Sequence Number Central	380
Date of Initial Diagnosis	390
Primary Site	400
Laterality	410
Diagnostic Confirmation	490
Types of Reporting Source	500
Histologic Type ICD-O-3 2001 and forward	522
Behavior 2001 and forward	523
Reporting Facility	540
NPI Reporting Facility (Derived)	545
Registry/Accession Number	550
Sequence Number Hospital	560
Abstractor Initials	570
Date of Admission/First Contact	580
Class of Case	610
Primary Payer at Dx	630
RX Hosp--Surg Prim Site 2023	671
RX Hosp--Scope Reg LN Sur	672
RX Hosp--Surg Oth Reg/Dis	674
Date of Reg LN Dissection	682
RX Hosp--Chemo	700

RX Hosp--Hormone	710
RX Hosp--BRM	720
RX Hosp--Other	730
Tumor Size Summary	756
Derived Summary Stage 2018	762
Summary Stage 2018	764
EOD Primary Tumor	772
EOD Regional Nodes	774
EOD Metastasis	776
Regional Nodes Positive	820
Regional Nodes Examined	830
Date of Sentinel Lymph Node Biopsy	832
Sentinel Lymph Nodes Examined	834
Sentinel Lymph Nodes Positive	835
AJCC TNM Clinical T	1001
AJCC TNM Clinical N	1002
AJCC TNM Clin M	1003
AJCC TNM Clin Stage Group	1004
AJCC TNM Path T	1011
AJCC TNM Path N	1012
AJCC TNM Path M	1013
AJCC TNM Path Stage Group	1014
AJCC TNM Post Therapy Path (yp) T	1021
AJCC TNM Post Therapy Path (yp) N	1022
AJCC TNM Post Therapy Path (yp) M	1023
AJCC TNM Post Therapy Path Stage Group	1024
AJCC TNM Clinical T Suffix	1031
AJCC TNM Path T Suffix	1032
AJCC TNM Post Therapy Path (yp) T Suffix	1033
AJCC TNM Clinical N Suffix	1034
AJCC TNM Path N Suffix	1035
AJCC TNM Post Therapy Path (yp) N Suffix	1036
AJCC Edition Number	1060
AJCC TNM Post Therapy Clin (yc) T	1062
AJCC TNM Post Therapy Clin (yc) T Suffix	1063
AJCC TNM Post Therapy Clin (yc) N	1064
AJCC TNM Post Therapy Clin (yc) N Suffix	1065
AJCC TNM Post Therapy Clin (yc) M	1066
Grade Post Therapy Clinical (yc)	1068
Mets at Diagnosis - Bone	1112
Mets at Diagnosis - Brain	1113
Mets at Diagnosis - Distant LNs	1114
Mets at Diagnosis - Liver	1115
Mets at Diagnosis - Lung	1116

Mets at Diagnosis - Other	1117
Lymphovascular Invasion	1182
Rx Date Surgery	1200
Rx Date Radiation	1210
Date Chemotherapy Started	1220
Date Hormone Therapy Started	1230
Date Immunotherapy Started	1240
Date Other Treatment Started	1250
Date of Initial Treatment	1260
Rx - Summary Treatment Status	1285
Rx Summ - Surg Primary Site 2023	1291
Rx Summary - Scope of Reg LN Surgery	1292
Rx Summary - Surgery Other/Dist Rx Code	1294
RX Summ - Surgical Margins	1320
RX Summ--Recon Breast	1335
Reason for No Surgery	1340
Rx Summary - Surgery/Radiation Sequence	1380
Chemotherapy	1390
Hormone Code	1400
Immunotherapy Code	1410
Other Treatment Code	1420
Reason for No Radiation	1430
Phase I Dose per Fraction	1501
Phase I Radiation External Beam Planning Tech	1502
Phase I Number of Fractions	1503
Phase I Radiation Primary Treatment Volume	1504
Phase I Radiation to Draining Lymph Nodes	1505
Phase I Radiation Treatment Modality	1506
Phase I Total Dose	1507
Phase II Dose per Fraction	1511
Phase II Radiation External Beam Planning Tech	1512
Phase II Number of Fractions	1513
Phase II Radiation Primary Treatment Volume	1514
Phase II Radiation to Draining Lymph Nodes	1515
Phase II Radiation Treatment Modality	1516
Phase II Total Dose	1517
Phase III Dose per Fraction	1521
Phase III Radiation External Beam Planning Tech	1522
Phase III Number of Fractions	1523
Phase III Radiation Primary Treatment Volume	1524
Phase III Radiation to Draining Lymph Nodes	1525
Phase III Radiation Treatment Modality	1526
Phase III Total Dose	1527
Radiation Treatment Discontinued Early	1531

Number of Phases of Rad Treatment to this Volume	1532
Total Dose	1533
Neoadjuvant Therapy	1632
Neoadjuvant Therapy-Clinical Response	1633
Neoadjuvant Therapy-Treatment Effect	1634
Rx Summary - Systemic/Surgery Sequence	1639
Date of Last Followup or Death	1750
Vital Status	1760
Cancer Status	1770
Date of Last Cancer (Tumor) Status	1772
Follow Up Source (Derived)	1790
Follow Up Source Central (TCR populated by linkages)	1791
Current Address City	1810
Current Address State	1820
Current Address - Zip Code	1830
Current Address Country	1832
Recurrence Date--1st	1860
Recurrence Type--1s	1880
Underlying Cause of Death	1910
ICD Code Revision Number for Cause of Death	1920
Place of Death - State	1942
Place of Death - Country	1944
Derived Summary Stage 2018	1975
Date Abstracted (Date Case Completed)	2090
CoC Accredited Flag	2152
Last Name	2230
Name--Birth Surname	2232
First Name	2240
Middle Name	2250
Name--Suffix	2270
Alias	2280
Medical Record Number	2300
Medicare Beneficiary Identifier	2315
Social Security Number	2320
Address at Dx Street Address	2330
Address at Dx Supplemental	2335
Current Address Number and Street	2350
Current Address Supplemental	2355
Telephone	2360
Physician Follow Up	2470
Text--DX Proc--PE	2520
Text--DX Proc--X-ray/Scan	2530
Text--DX Proc--Scopes	2540
Text--DX Proc--Lab Tests	2550

Text--DX Proc--Op	2560
Text--DX Proc--Path	2570
Final Dx Primary Site and Laterality	2580
Final Dx Morph/Beh/Grade	2590
Summary Stage Documentation	2600
Rx Text - Surgery	2610
Rx Text - Chemotherapy	2640
Rx Text - Hormone	2650
Rx Text - Immunotherapy	2660
Rx Text - Other	2670
Other Pertinent Information	2680
Rx Date Mst Defn Srg	3170
Rx Date - Systemic	3230
Rx Summary Transplant/Endocrine	3250
SEER Site Specific Factor 1	3700
Secondary Diagnosis 1	3780
Secondary Diagnosis 2	3782
Secondary Diagnosis 3	3784
Secondary Diagnosis 4	3786
Secondary Diagnosis 5	3788
Secondary Diagnosis 6	3790
Secondary Diagnosis 7	3792
Secondary Diagnosis 8	3794
Secondary Diagnosis 9	3796
Secondary Diagnosis 10	3798
Chromosome 1p: Loss of Heterozygosity (LOH)	3801
Chromosome 19q: Loss of Heterozygosity (LOH)	3802
Adenoid Cystic Basaloid Pattern	3803
Adenopathy	3804
AFP Post-Orchiectomy Lab Value	3805
AFP Post-Orchiectomy Range	3806
AFP Pre-Orchiectomy Lab Value	3807
AFP Pre-Orchiectomy Range	3808
AFP Pretreatment Interpretation	3809
AFP Pretreatment Lab Value	3810
Anemia	3811
B symptoms	3812
Bilirubin Pretreatment Total Lab Value	3813
Bilirubin Pretreatment Unit of Measure	3814
Bone Invasion	3815
Brain Molecular Markers	3816
Breslow Tumor Thickness	3817
CA-125 Pretreatment Interpretation	3818
CEA Pretreatment Interpretation	3819

CEA Pretreatment Lab Value	3820
Chromosome 3 Status	3821
Chromosome 8q Status	3822
Circumferential Resection Margin (CRM)	3823
Creatinine Pretreatment Lab Value	3824
Creatinine Pretreatment Unit of Measure	3825
Estrogen Receptor Percent Positive or Range	3826
Estrogen Receptor Summary	3827
Esophagus and EGJ Tumor Epicenter	3829
Extranodal Extension Clin (non-Head and Neck)	3830
Extranodal Extension Head and Neck Clinical	3831
Extranodal Extension Head and Neck Pathological	3832
Extranodal Extension Path (non-Head and Neck)	3833
Extravascular Matrix Patterns	3834
Fibrosis Score	3835
FIGO Stage	3836
Gestational Trophoblastic Prognostic Scoring Index	3837
Gleason Patterns Clinical	3838
Gleason Patterns Pathological	3839
Gleason Score Clinical	3840
Gleason Score Pathological	3841
Gleason Tertiary Pattern	3842
Grade Clinical	3843
Grade Pathological	3844
Grade Post Therapy Path (yp)	3845
hCG Post-Orchiectomy Lab Value	3846
hCG Post-Orchiectomy Range	3847
hCG Pre-Orchiectomy Lab Value	3848
hCG Pre-Orchiectomy Range	3849
HER2 Overall Summary	3855
Heritable Trait	3856
High Risk Cytogenetics	3857
High Risk Histologic Features	3858
HIV Status	3859
International Normalized Ratio Prothrombin Time	3860
Ipsilateral Adrenal Gland Involvement	3861
JAK2	3862
Ki-67	3863
Invasion Beyond Capsule	3864
KIT Gene Immunohistochemistry	3865
KRAS	3866
LDH Post-Orchiectomy Range	3867
LDH Pre-Orchiectomy Range	3868
LDH Level	3869

LDH Upper Limits of Normal	3870
LN Assessment Method Femoral-Inguinal	3871
LN Assessment Method Para-Aortic	3872
LN Assessment Method Pelvic	3873
LN Distant Assessment Method	3874
LN Distant: Mediastinal, Scalene	3875
LN Head and Neck Levels I-III	3876
LN Head and Neck Levels IV-V	3877
LN Head and Neck Levels VI-VII	3878
LN Head and Neck Other	3879
LN Isolated Tumor Cells (ITC)	3880
LN Laterality	3881
LN Positive Axillary Level I-II	3882
LN Size	3883
LN Status Femoral-Inguinal, Para-Aortic, Pelvic	3884
Lymphocytosis	3885
Major Vein Involvement	3886
Measured Basal Diameter	3887
Measured Thickness	3888
Methylation of O6-Methylguanine-Methyltransferase	3889
Microsatellite Instability (MSI)	3890
Microvascular Density	3891
Mitotic Count Uveal Melanoma	3892
Mitotic Rate Melanoma	3893
Multigene Signature Method	3894
Multigene Signature Results	3895
NCCN International Prognostic Index (IPI)	3896
Number of Cores Examined	3897
Number of Cores Positive	3898
Number of Examined Para-Aortic Nodes	3899
Number of Examined Pelvic Nodes	3900
Number of Positive Para-Aortic Nodes	3901
Number of Positive Pelvic Nodes	3902
Oncotype Rx Recurrence Score - DCIS	3903
Oncotype Rx Recurrence Score - Invasive	3904
Oncotype Rx Risk Level - DCIS	3905
Oncotype Rx Risk Level - Invasive	3906
Organomegaly	3907
Percent Necrosis Post Neoadjuvant	3908
Perineural Invasion	3909
Peripheral Blood Involvement	3910
Peritoneal Cytology	3911
Pleural Effusion	3913
Progesterone Receptor Percent Positive or Range	3914

Progesterone Receptor Summary	3915
Progesterone Receptor Total Allred Score	3916
Profound Immune Suppression	3918
EOD Prostate Pathologic Extension	3919
PSA (Prostatic Specific Antigen) Lab Value	3920
Residual Tumor Volume Post Cytoreduction	3921
Response to Neoadjuvant Therapy	3922
S Category Clinical	3923
S Category Pathological	3924
Sarcomatoid Features	3925
Schema Discriminator 1	3926
Schema Discriminator 2	3927
Schema Discriminator 3	3928
Separate Tumor Nodules	3929
Serum Albumin Pretreatment Level	3930
Serum Beta-2 Microglobulin Pretreatment Level	3931
LDH Lab Value	3932
Thrombocytopenia	3933
Tumor Deposits	3934
Ulceration	3936
Visceral and Parietal Pleural Invasion	3937
ALK Rearrangement	3938
EGFR Mutational Analysis	3939
BRAF Mutational Analysis	3940
NRAS Mutational Analysis	3941
CA 19-9 PreTx Lab Value	3942
Macroscopic Evaluation of Mesorectum	3950
p16	3956
LN Status Pelvic	3957
LN Status Pelvic Para-Aortic	3958
Ln Status Femoral-Inguinal	3959
Histologic Subtype	3960
Clinical Margin Width	3961
Brain Primary Tumor Location	3964
RX Text -Radiation, Radiation Modality	2620, 2630

Collection Dates

2003-Present
2024-Present
1995-Present
1995-Present
1995-Present
1995-Present
2013-Present
2022-Present
1995-Present
2001-Present
2001-Present
2001-Present
2001-Present
1995-Present
1995-Present
1995-Present
1995-Present
2013-Present
2013-Present
2010-Present
2010-Present
2022-Present
1995-Present
1995-Present
1995-Present
1995-Present
1995-Present
1995-Present
2001-Present
2001-Present
1995-Present
2009-Present
1995-Present
1995-Present
1995-Present
1995-Present
1998-Present
2007-Present
2023-Present
2022-Present
2022-Present
2022-Present
2022-Present

D

2022-Present
2022-Present
2022-Present
2016-Present
2023-Present
2018-Present
2022-Present
2022-Present
2022-Present
1998-Present
1998-Present
2022-Present
2022-Present
2022-Present
2018-Present
2018-Present
2018-Present
2018-Present
2018-Present
2018-Present
2018-Present
2018-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2015-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2021-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present

[illegible]

2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2006-Present
1995-Present
1995-Present
2022-Present
2022-Present
2009-Present
2006-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2013-Present
2013-Present
2024-Present
1995-Present
2018-Present
1995-Present
2021-Present
1995-Present
1995-Present
2022-Present
2006-Present
1995-Present
2021-Present
1995-Present
1995-Present
2006-Present
2022-Present
2022-Present
2022-Present
2006-Present
1995-Present
1995-Present
1995-Present
1995-Present

1995-Present
1995-Present
1995-Present
1995-Present
1995-Present
2004-Present
2004-Present
2004-Present
2004-Present
2004-Present
1995-Present
2015-Present
2022-present
2003-Present
2022-Present
2023-Present
2023-Present
2023-Present
2023-Present
2023-Present
2023-Present
2023-Present
2023-Present
2023-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2022-Present
2018-Present
2018-Present
2022-Present
2022-Present

[illegible]

[illegible]

[illegible]